Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A18-71
Last updated

Report documents

  1. Extract of dossier assessment

    Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 135 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 135 kB, EN, not accessible)

  2. Dossier assessment

    Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 600 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 600 kB, DE, not accessible)

Dossier assessment

Indication:

Prophylaxis of migraine

Result of dossier assessment:

Patients who do not respond to other drug classes, or do not tolerate them, or for whom these are unsuitable: indication of considerable added benefit. Patients with other treatment options: added benefit not proven.

Press releases

Erenumab in migraine: indication of considerable added benefit for certain patients

Successful prophylaxis if other drug treatment options have been exhausted
Press release

Additional information

Federal Joint Committee (G-BA)

2019-09-19 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A18-71
Commission
Commission awarded on 29.10.2018 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)

    Project no.
    A21-58
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page